Hybridoma technology is a technique used to produce large quantities of identical antibodies (monoclonal antibodies). It involves fusing antibody- producing B lymphocytes (obtained from an animal immunized with a specific antigen) with myeloma cells (cancerous plasma cells). The resulting hybrid cells, called hybridomas, possess both the antibody- producing ability of the B cells and the immortality of the myeloma cells, allowing them to be cultured indefinitely to produce monoclonal antibodies.